(MIT Technology Review) – The CRISPR patents are back in play.

On Monday, the US Court of Appeals for the Federal Circuit said scientists Jennifer Doudna and Emmanuelle Charpentier will get another chance to show they ought to own the key patents on what many consider the defining biotechnology invention of the 21st century.

The pair shared a 2020 Nobel Prize for developing the versatile gene-editing system, which is already being used to treat various genetic disorders, including sickle cell disease.  (Read More)